Regeneron Pharmaceuticals
Open
$615.07
Prev. Close
$615.04
High
$615.45
Low
$614.42
Market Snapshot
$64.99B
14.7
40.89
$14.2B
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 15,410 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.
Regeneron Pharmaceuticals has consistently outperformed the market over the past two decades, achieving an impressive annual return of 21.59%.
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 15,410 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others.
Recently from Cashu
Regeneron's Maftivimab Prioritized by WHO Amid Current Ebola Outbreak in Africa
Regeneron Pharmaceuticals (Ticker: REGN) is making strides in global health as its Ebola treatment, Inmazeb, gains attention. Recently, the World Health Organization’s Therapeutics Advisory Group prio…
Regeneron Advances COPD Treatment with Tozorakimab, Targeting Inflammation and Mucus Dysfunction
Title: Regeneron Pharmaceuticals Advances COPD Treatment with Tozorakimab Regeneron Pharmaceuticals focuses on developing innovative therapies for chronic inflammatory diseases, with a recent emphasis…
Regeneron Pharmaceuticals: Potential Undervaluation Amid Strong Product Portfolio and Innovation
Unpacking Regeneron Pharmaceuticals' Market Valuation Relative to Competitors in the Biotech Sector As of October 2023, Regeneron Pharmaceuticals stands at a pivotal point within the biotechnology ind…
Regeneron Pharmaceuticals: Undervalued with Strong Growth Potential Despite Low P/E Ratio
Regeneron Pharmaceuticals: Evaluating Competitive Positioning Through P/E Ratios In the current landscape of biotechnology, Regeneron Pharmaceuticals stands out with a price-to-earnings (P/E) ratio of…